Chimeric Therapeutics Ltd has released a press release.
Entitlement Offer to raise approximately $18.1 million
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
In the deck
Earlier from Chimeric Therapeutics
- Encouraging data from 2nd dose cohort in CLTX CAR T trial
- Sponsored Research Agreement with University of Pennsylvania
- Chimeric receives US patent covering CLTX CAR technology
- Transformative Portfolio Expansion Presentation
- CLTX CAR T data shows regional control of tumour recurrence
Later from Chimeric Therapeutics
- Successful completion of Institutional Entitlement Offer
- Chimeric partners with be the match biotherapies
- Final Results in Phase 1 Trial of CORE NK Platform
- Security Class Suspension from Quotation CHMO
- Completion of retail component of Entitlement Offer
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics